Research programme: CNS disorders therapeutics - Anavex Life Sciences

Drug Profile

Research programme: CNS disorders therapeutics - Anavex Life Sciences

Alternative Names: ANAVEX 1-41; ANAVEX 19-144

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Anavex Life Sciences
  • Class Furans; Small molecules
  • Mechanism of Action Calcium channel antagonists; Chloride channel modulators; Muscarinic M1 receptor agonists; Muscarinic M2 receptor antagonists; Muscarinic M3 receptor antagonists; NMDA receptor antagonists; Serotonin modulators; Sigma-1 receptor agonists; Sodium channel antagonists; Sodium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Major depressive disorder; Parkinson's disease; Stroke
  • Discontinued Epilepsy

Most Recent Events

  • 27 Nov 2017 Preclinical development for Alzheimer's disease is underway in Europe (IV) (Anavex pipeline, November 2017)
  • 27 Nov 2017 Preclinical development for Alzheimer's disease is underway in Europe (PO) (Anavex pipeline, November 2017)
  • 27 Nov 2017 Preclinical development for Stroke is underway in Germany (Anavex pipeline, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top